In the present study, we set out to characterize the suitability of targeting B7-H3 with a novel Fc-optimized mAb termed B7-H3-SDIE as immunotherapeutic treatment option for pancreatic cancer. The gene discussed is CD276; the disease is familial pancreatic carcinoma.